Embecta Corp. (EMBC) Securities Class Action Lawsuit Update

• Company: Embecta Corp. (NASDAQ: EMBC)
• Lead Plaintiff Deadline: August 17, 2026
• Class Period: November 25, 2025 - May 4, 2026
• Stock Drop: May 5, 2026 - EMBC fell $5.35 (57.8%) to $3.90
• Lawsuit Type: Securities Class Action

Introduction

On June 17, 2026, a federal securities class action was filed in the United States District Court for the District of New Jersey against Embecta Corp. (NASDAQ: EMBC), its President and Chief Executive Officer Devdatt Kurdikar, and its Senior Vice President and Chief Financial Officer Jacob P. Elguicze. The lawsuit covers a class period from November 25, 2025 through May 4, 2026, inclusive, and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

At the heart of the Embecta securities class action is an alleged gap between management’s public confidence and the company’s later-disclosed results. Throughout the class period, defendants painted a picture of stability and resilience, reaffirming revenue guidance and celebrating the durability of the company's pen needle franchise. CEO Kurdikar described the pen needle business as "incredibly resolute" at a major healthcare conference in January 2026. Weeks later, on the first quarter earnings call, management reaffirmed every key financial metric. The complaint alleges investors purchased shares against a backdrop of those reassurances.

The complaint alleges the truth emerged on May 5, 2026, when Embecta disclosed second quarter fiscal 2026 results revealing a 14.4% year-over-year revenue decline, far worse than the company's previously reaffirmed fiscal 2026 adjusted constant-currency revenue guidance of flat to down 2%. The company slashed its full-year revenue outlook by roughly $57 million at the midpoint and cut its adjusted earnings per share guidance by approximately 40%. A key driver was weakness in the segment management had highlighted: U.S. pen needle sales, including share loss and retail market volume softness. EMBC shares cratered from $9.25 to $3.90 in a single trading session, a loss of over 57.8%, erasing hundreds of millions of dollars in market capitalization.

Backdrop and Business Context

Embecta Corp. traces its origins to 1924, when Becton, Dickinson and Company first began developing insulin delivery devices. For nearly a century, that diabetes care franchise grew within BD, ultimately serving more than 30 million people across over 100 countries. On April 1, 2022, BD completed the spin-off of its Diabetes Care business into an independent, publicly traded entity, Embecta Corp., which began trading on the Nasdaq Global Select Market under the ticker EMBC. BD shareholders received one share of Embecta for every five BD shares held, and BD retained no ownership interest following the separation.

Embecta operates as a global medical device company focused on insulin delivery products. Its core portfolio consists of pen needles, insulin syringes, and safety injection devices, all single-use consumables that generate recurring demand from patients who inject insulin daily. The company is widely described as the largest manufacturer of insulin injection devices in the world, producing approximately 8 billion injection devices annually. Embecta reported fiscal year 2025 revenue of approximately $1.08 billion. Its principal competitors in insulin delivery include Novo Nordisk, Ypsomed, Terumo, and Owen Mumford, while insulin pump manufacturers such as Insulet and Medtronic represent technology-based substitutes.

Embecta's business model depends heavily on stable prescription volumes for insulin pens and on maintaining preferred access positions with major pharmacy customers. According to the complaint, it was precisely these dependencies that allegedly undermined the company's guidance during the class period: competitive share loss concentrated at a single large customer, softening retail prescription volumes, and patients migrating to lower-cost channels where Embecta does not participate.

Promises Made vs. Reality

Throughout the class period, Embecta's leadership projected confidence about the company's trajectory and the durability of its core product segments. On November 25, 2025, as the company reported fiscal year 2025 results and issued initial 2026 guidance, CEO Kurdikar told investors the company intended to "maintain our global leadership position in our core product categories" and emphasized that Embecta's "global scale, resilient supply chain, and experienced teams" positioned the company well. CFO Elguicze laid out specific financial expectations on the same earnings call, guiding for adjusted constant currency revenue of flat to down 2% compared to 2025, translating into an as-reported revenue range of $1.071 billion to $1.093 billion. Adjusted operating margin was forecast at 29% to 30%, and adjusted diluted earnings per share were expected to land between $2.80 and $3.00.

The messaging intensified at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Kurdikar walked analysts through years of revenue data to underscore the stability of Embecta's product portfolio, characterizing pen needle revenue as having "stayed stable throughout" a period marked by pump adoption and GLP-1 growth. When asked directly about pen needle resilience, Kurdikar stated the business was "incredibly resolute," pointing to the global patient population, the medically necessary nature of the products, and new prescription trends for insulin pens that were "showing a slight positive trend." He emphasized that approximately 85% of Embecta's portfolio was pen needles and safety pen needles, framing the segment as the bedrock of the company's revenue stability.

On February 5, 2026, Embecta published first quarter 2026 results and formally reaffirmed all previously provided guidance ranges. Kurdikar stated on the earnings call, "Today, we reaffirmed our previously provided financial guidance ranges." Elguicze echoed this, walking through revenue, foreign exchange, operating margin, and earnings per share guidance line by line, confirming each was unchanged. The CFO did note the company expected to land "closer to the lower end" of its revenue and margin ranges due to "incremental headwinds" in the U.S. during the first half of the year, but the guidance ranges themselves remained intact.

The complaint characterizes the May 5, 2026 disclosures as revealing a sharp contrast with those earlier assurances. The same pen needle franchise Kurdikar had called "incredibly resolute" just weeks earlier was revealed to be in steep decline. Second quarter revenue fell 14.4% year over year on an as-reported basis, and 17.4% on an adjusted constant currency basis, far worse than the company's previously reaffirmed fiscal 2026 adjusted constant-currency revenue guidance of flat to down 2%. U.S. revenue alone plunged 29.4%. Kurdikar acknowledged that "the largest contributor to the lower year-over-year U.S. revenue is share loss within our pen needle product category, most of which is concentrated at a single customer," adding that overall market volume softness for insulin pens and pen needles in the retail channel was a significant factor. The company slashed its full-year revenue guidance to $1.015 billion to $1.035 billion and cut adjusted EPS guidance to $1.55 to $1.75, a reduction of approximately 40% at the midpoint. The company also reduced its quarterly dividend from $0.15 to $0.01 per share.

As alleged in the complaint, defendants knew or recklessly disregarded that U.S. pen needle weakness, competitive share loss at a major customer, and deteriorating retail market volumes were likely to render the company's original revenue guidance unattainable, yet they continuously reaffirmed that guidance and publicly championed the very segment that was faltering.

Timeline of Alleged Misconduct and Disclosures

Class Period: November 25, 2025 - May 4, 2026, inclusive.

November 25, 2025: Class period opens. Embecta publishes Q4 and full year fiscal 2025 results and issues initial fiscal year 2026 guidance. CEO Kurdikar touts global scale and resilient supply chain. CFO Elguicze guides for revenue of $1.071 billion to $1.093 billion, adjusted operating margin of 29% to 30%, and adjusted EPS of $2.80 to $3.00.

January 14, 2026: CEO Kurdikar presents at the 44th Annual J.P. Morgan Healthcare Conference. Describes pen needle business as "incredibly resolute" and highlights stable pen needle revenue, new prescription trends, and geographic diversification. States approximately 85% of portfolio is pen needles and safety pen needles.

February 5, 2026: Embecta reports Q1 fiscal 2026 results. CEO Kurdikar states results were "largely consistent with our expectations." Company formally reaffirms all previously provided 2026 guidance ranges. CFO Elguicze reaffirms revenue, operating margin, and EPS guidance, noting expectation to be closer to the lower end of ranges.

May 5, 2026: Alleged Corrective Disclosure. Embecta publishes Q2 fiscal 2026 results revealing revenue of $221.8 million, down 14.4% year over year. U.S. revenue declines 29.4%. Company attributes decline primarily to pen needle share loss concentrated at a single customer and overall market volume softness. Embecta lowers full-year 2026 revenue guidance to $1.015 billion to $1.035 billion and cuts adjusted EPS guidance to $1.55 to $1.75. Quarterly dividend reduced from $0.15 to $0.01 per share. EMBC stock falls from $9.25 to $3.90, a decline of over 57.8%.

May 6, 2026: Analyst downgrades follow. BTIG downgrades EMBC to Neutral from Buy, citing a "major miss" and "guidance cut." Wolfe Research publishes report titled "Ouch! Injection of FY2Q26 Info Stings. US Needs a Bandaid." Mizuho lowers price target to $5.00 from $12.00.

June 17, 2026: Securities class action complaint filed in the U.S. District Court for the District of New Jersey.

Investor Harm and Market Reaction

The alleged corrective disclosure on May 5, 2026 was followed by a significant decline in Embecta's stock price. When the company revealed that second quarter revenue had declined 14.4% year over year and slashed its full-year guidance, EMBC shares plummeted from a closing price of $9.25 on May 4, 2026, to $3.90 on May 5, 2026. That single-day decline of $5.35 per share represented a loss of over 57.8%, wiping out more than half the stock's value in a matter of hours.

Analyst reports also reacted sharply to the miss. BTIG characterized the results as a "major miss" and immediately downgraded the stock to Neutral from Buy. Wolfe Research noted that EMBC was trading at approximately 2.5 times its new fiscal 2026 earnings estimate, reflecting the market's abrupt repricing of the company's prospects. Mizuho slashed its price target from $12.00 to $5.00, warning that "visibility on time to stabilizing volumes" remained unclear. The analyst response supports the complaint's theory that the May 5 disclosure sharply contrasted with management's earlier confidence.

The damage was compounded by the scope of the guidance revision. The $57 million midpoint reduction in revenue guidance and the approximately 40% cut to adjusted EPS guidance indicated that management expected the share loss and market softness to persist for the remainder of fiscal 2026. Management’s updated assumptions support the complaint’s allegation that the prior guidance rested on assumptions already being undermined by U.S. pen needle weakness.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all defendants, and under Section 20(a) of the Exchange Act against the individual defendants as controlling persons of Embecta.

The defendants are Embecta Corp. itself, CEO and President Devdatt Kurdikar, and Senior Vice President and Chief Financial Officer Jacob P. Elguicze.

Scienter allegations center on the individual defendants' positions of authority and their access to internal information regarding the performance of Embecta's U.S. pen needle business, competitive dynamics at key customer accounts, and the attainability of the company's fiscal year 2026 guidance. The complaint emphasizes the temporal proximity between defendants' reaffirmation of guidance and public celebration of the pen needle segment's strength and the subsequent disclosure of materially adverse results, arguing this proximity weighs heavily in favor of intentional or reckless conduct. No insider trading activity or confidential witness testimony is cited in the complaint.

Procedurally, the case was filed on June 17, 2026, and is in its earliest stages. The lead plaintiff deadline is August 17, 2026. The complaint seeks class treatment under Federal Rule of Civil Procedure 23(a) and (b)(3) on behalf of all persons who purchased or otherwise acquired Embecta common stock during the class period and were damaged upon the revelation of the alleged corrective disclosure.

SEC Filings, Earnings Releases & Public Statements

The complaint's allegations are grounded in public statements made during earnings calls, press releases, and a major investor conference presentation rather than in specific periodic SEC filing disclosures. The core pattern identified in the complaint is one of continuous public reaffirmation of financial guidance that was allegedly misleading, set against a backdrop of deteriorating fundamentals that defendants knew or recklessly disregarded.

On November 25, 2025, Embecta's fiscal year 2025 earnings release and accompanying earnings call established the baseline 2026 guidance framework. CFO Elguicze presented detailed assumptions across revenue, operating margin, earnings per share, foreign exchange, and tax rate, projecting revenue of $1.071 billion to $1.093 billion and adjusted EPS of $2.80 to $3.00. The guidance acknowledged known headwinds, including modest syringe volume declines in the U.S. and increased cannula costs, but framed these as manageable within the stated ranges.

On February 5, 2026, in connection with first quarter 2026 results, Embecta formally reaffirmed all guidance ranges. The CFO walked through each metric individually, confirming no changes. The only qualification was that results were expected to come in "closer to the lower end" of the ranges due to "incremental headwinds" in the U.S. during the first half of the year. The complaint alleges this characterization materially understated the severity of the challenges facing the U.S. pen needle business.

The alleged corrective disclosure on May 5, 2026 revealed a dramatically different picture. Revenue had declined 14.4% year over year on an as-reported basis, with U.S. revenue down 29.4%. The company disclosed that pen needle share loss, concentrated at a single major customer, accounted for approximately $25 million of the $75 million revenue guidance reduction, while overall market volume softness contributed approximately $20 million. Additional factors, including inventory reductions, incremental pricing pressure, syringe declines related to compounded drug usage, the discontinuation of the swab product line, and reduced safety product growth expectations, comprised the remainder. The full-year adjusted EPS range was reduced from $2.80 to $3.00 to $1.55 to $1.75.

The complaint alleges that the gap between the guidance reaffirmed in February and the results disclosed in May reflects a failure to disclose material adverse trends that were known or recklessly disregarded. In particular, the complaint contends that defendants were aware that competitive dynamics at a key customer, patient migration to lower-cost channels, and softening retail prescription volumes for insulin pens were undermining the assumptions embedded in the company's guidance. Management's characterization of the pen needle business as "incredibly resolute" at the J.P. Morgan conference on January 14, 2026, allegedly occurred against a backdrop of deterioration that rendered that description materially misleading.

How to Check Whether You May Be Eligible in the Embecta Corp. (EMBC) Class Action

• Confirm you purchased or otherwise acquired EMBC common stock during the November 25, 2025 to May 4, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding lead plaintiff deadlines, eligibility, and recovery rights

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.